Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody tested to tame childhood arthritis and cut steroid use

NCT ID NCT05925452

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing an experimental drug called GenaKumab in children and teens with active systemic juvenile idiopathic arthritis, a condition that causes joint inflammation and recurring fevers. The trial enrolls about 290 participants aged 2 to under 18 who have had symptoms for at least two months. Participants receive GenaKumab or a comparison treatment by injection every four weeks. The main goal is to see whether the drug helps children safely reduce their use of glucocorticoid steroids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental antibody drug called GenaKumab
What this could lead to
If it works, GenaKumab could offer children with systemic juvenile idiopathic arthritis a new treatment option and help them take lower doses of steroids.
What could go wrong
The drug is still experimental and may not control the disease better than existing treatments. It could cause side effects, and results in a trial may not apply to every child with this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 290 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients, with the remaining before age 2 years old or more and \& lt; 18 years old; * 2001 ILAR classification criteria for the diagnosis of confirmed sJIA 2 or more months: onset age must \& lt; At 16 years of age, symptoms included: ≥1 case of arthritis, accompanied by or prior to ≥2 weeks of recurrent fever, including remittenor fever for ≥3 consecutive days (maximum daily body temperature ≥39 ° C, body temperature falling below 37 ° C between 2 heat peaks), accompanied by at least one of the following symptoms: ① a transient, non-fixed erythematous rash; ② systemic lymph node enlargement; Swelling of the liver and/or spleen; ④ Serositis. * Agree to use effective means of contraception throughout the study period and for 6 months after the end of treatment. Exclusion Criteria: * Pregnant or lactating female subjects * A history of allergic reactions to investigational drugs or to molecules with similar structures; Those who cannot be given intramuscular injections; * History of pericarditis, myocarditis, serositis, bacterial heart valve or endocarditis within 6 months before screening; Patients who had been diagnosed with MAS within 6 months prior to screening, or had relevant symptoms and signs at screening, and were suspected of having MAS as assessed by the investigators; * There are other rheumatic diseases such as Kawasaki disease, polyarteritis nodosa and so on. History of autoinflammatory diseases such as familial Mediterranean fever, high IgD syndrome, NLRP3-related autoinflammatory diseases; * Patients with a history of interstitial lung disease, pulmonary fibrosis, alveolar proteinosis, or pulmonary hypertension; Patients with a history of repeated invasive fungal infection; In the 7 days prior to randomization, there were infections that required control with systemic antigenic microbiotics (including antibacterial, antiviral, antifungal, etc.); * Subjects with a history of TB exposure or suspected TB symptoms.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Active systemic juvenile idiopathic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Pediatric Hospital of Fudan University

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 201102, China

  • Chengdu Women and Children's Central Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610073, China

  • Children's Hospital Affiliated to Capital Medical University

    RECRUITING

    Beijing, Benjing, 100045, China

  • Children's Hospital Affiliated to Chongqing Medical University

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, 400015, China

  • Children's Hospital Affiliated to Nanjing Medical University

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, 210008, China

  • Children's Hospital of Soochow University

    NOT_YET_RECRUITING

    Suzhou, Jiangsu, 215002, China

  • Children's Hospital, Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310016, China

  • Hunan Children's Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, 410323, China

  • The Second Affiliated Hospital of Wenzhou Medical University

    NOT_YET_RECRUITING

    Wenzhou, Zhejiang, 325099, China

  • Xi'an Children's Hospital

    NOT_YET_RECRUITING

    Xi’an, Shanxi, 710002, China